These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 20622899)

  • 1. PBK/TOPK interacts with the DBD domain of tumor suppressor p53 and modulates expression of transcriptional targets including p21.
    Hu F; Gartenhaus RB; Eichberg D; Liu Z; Fang HB; Rapoport AP
    Oncogene; 2010 Oct; 29(40):5464-74. PubMed ID: 20622899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PBK/TOPK in the differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma and its involvement in prognosis of human cholangiocarcinoma.
    He F; Yan Q; Fan L; Liu Y; Cui J; Wang J; Wang L; Wang Y; Wang Z; Guo Y; Huang G
    Hum Pathol; 2010 Mar; 41(3):415-24. PubMed ID: 19954816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of Polo like kinase 1 (PLK1) by p21(Waf1) mediates the p53-dependent prevention of caspase-independent mitotic death.
    Lin YC; Sun SH; Wang FF
    Cell Signal; 2011 Nov; 23(11):1816-23. PubMed ID: 21726628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
    Shin DY; Sung Kang H; Kim GY; Kim WJ; Yoo YH; Choi YH
    Biomed Pharmacother; 2013 May; 67(4):305-11. PubMed ID: 23582784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitotic kinase PBK/TOPK as a therapeutic target for adult T‑cell leukemia/lymphoma.
    Ishikawa C; Senba M; Mori N
    Int J Oncol; 2018 Aug; 53(2):801-814. PubMed ID: 29901068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PBK/TOPK mediates promyelocyte proliferation via Nrf2-regulated cell cycle progression and apoptosis.
    Liu Y; Liu H; Cao H; Song B; Zhang W; Zhang W
    Oncol Rep; 2015 Dec; 34(6):3288-96. PubMed ID: 26503118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response.
    Ayllón V; O'connor R
    Oncogene; 2007 May; 26(24):3451-61. PubMed ID: 17160018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation.
    Zeng PY; Berger SL
    Cancer Res; 2006 Nov; 66(22):10701-8. PubMed ID: 17108107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PBK/TOPK expression correlates with mutant p53 and affects patients' prognosis and cell proliferation and viability in lung adenocarcinoma.
    Lei B; Qi W; Zhao Y; Li Y; Liu S; Xu X; Zhi C; Wan L; Shen H
    Hum Pathol; 2015 Feb; 46(2):217-24. PubMed ID: 25466965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E2F1-dependent pathways are involved in amonafide analogue 7-d-induced DNA damage, G2/M arrest, and apoptosis in p53-deficient K562 cells.
    Li Y; Shao J; Shen K; Xu Y; Liu J; Qian X
    J Cell Biochem; 2012 Oct; 113(10):3165-77. PubMed ID: 22593008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer.
    Park JH; Lin ML; Nishidate T; Nakamura Y; Katagiri T
    Cancer Res; 2006 Sep; 66(18):9186-95. PubMed ID: 16982762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PBK/TOPK expression in non-small-cell lung cancer: its correlation and prognostic significance with Ki67 and p53 expression.
    Lei B; Liu S; Qi W; Zhao Y; Li Y; Lin N; Xu X; Zhi C; Mei J; Yan Z; Wan L; Shen H
    Histopathology; 2013 Nov; 63(5):696-703. PubMed ID: 24025073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma.
    Ohashi T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Imamura T; Kiuchi J; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
    Br J Cancer; 2017 Jan; 116(2):218-226. PubMed ID: 27898655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress.
    Li J; Tan J; Zhuang L; Banerjee B; Yang X; Chau JF; Lee PL; Hande MP; Li B; Yu Q
    Cancer Res; 2007 Dec; 67(23):11317-26. PubMed ID: 18056458
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel TOPK inhibitor HI-TOPK-032 effectively suppresses colon cancer growth.
    Kim DJ; Li Y; Reddy K; Lee MH; Kim MO; Cho YY; Lee SY; Kim JE; Bode AM; Dong Z
    Cancer Res; 2012 Jun; 72(12):3060-8. PubMed ID: 22523035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of PBK/TOPK Contributes to Tumor Development and Poor Outcome of Esophageal Squamous Cell Carcinoma.
    Ohashi T; Komatsu S; Ichikawa D; Miyamae M; Okajima W; Imamura T; Kiuchi J; Nishibeppu K; Kosuga T; Konishi H; Shiozaki A; Fujiwara H; Okamoto K; Tsuda H; Otsuji E
    Anticancer Res; 2016 Dec; 36(12):6457-6466. PubMed ID: 27919968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-216b-3p inhibits lung adenocarcinoma cell growth via regulating PDZ binding kinase/T-LAK-cell-originated protein kinase.
    Chai Y; Xue H; Wu Y; Du X; Zhang Z; Zhang Y; Zhang L; Zhang S; Zhang Z; Xue Z
    Exp Ther Med; 2018 Jun; 15(6):4822-4828. PubMed ID: 29805502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuation of DNA damage checkpoint by PBK, a novel mitotic kinase, involves protein-protein interaction with tumor suppressor p53.
    Nandi AK; Ford T; Fleksher D; Neuman B; Rapoport AP
    Biochem Biophys Res Commun; 2007 Jun; 358(1):181-8. PubMed ID: 17482142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells.
    Zhu F; Zykova TA; Kang BS; Wang Z; Ebeling MC; Abe Y; Ma WY; Bode AM; Dong Z
    Gastroenterology; 2007 Jul; 133(1):219-31. PubMed ID: 17631144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.
    Fischer M; Quaas M; Nickel A; Engeland K
    Oncotarget; 2015 Dec; 6(39):41402-17. PubMed ID: 26595675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.